Next Generation Cancer Diagnostic Devices market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Next Generation Cancer Diagnostic Devices market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Next Generation Cancer Diagnostic Devices market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Next Generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC)
Protein Microarrays
DNA Microarrays
Reverse Transcriptase-PCR (RT-PCR)
Segment by Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Roche Holding Ltd.?Switzerland)
Abbott Laboratories(US)
Siemens Healthcare(Germany)
Agilent Technologies Inc(Germany)
Illumina Inc.(US)
Becton Dickinson and Co.(US)
QIAGEN N.V.(Germany)
Affymetrix Inc.(US)
Johnson & Johnson(US)
Thermo Fisher Scientific Inc.(US)
GE Healthcare(England)
Life Technologies Corp.(US)
Luminex Corp.(US)
Cepheid Inc.(US)
Allegro Diagnostics Corp.(Brazil)
